TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05970497: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies

Sponsor: Krystal Biotech, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,246,700

Rescue Site Savings

+$5,458,530

Unlock Full NCT05970497 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05970497 Rescue Dossier →